Several clinical trials are currently ongoing using the first in class orally bioavailable BCL2-selective BH3-mimetic venetoclax, demonstrating clinical efficacy as a single agent in several B cell malignancies such as CLL, MCL, and MM (17–21). Here, BCL2 is linked to Miyoshi myopathy.